ADEQUAN I.M. MULTI-DOSE
$350.00
ADEQUAN I.M. MULTI-DOSE 100 m/50 mL Preserved Multi-Dose Vial
For Intramuscular Use In Horses and camel Only. Not for Intra-Articular Use.Each mL contains Polysulfated Glycosaminoglycan (PSGAG) 100 mg, Benzyl Alcohol 0.9% v/v as a preservative, and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. The solution is clear, colorless to slightly yellow.
Polysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpal and hock joints
INDICATIONS:
Adequan i.m. Multi-Dose is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
DOSAGE AND ADMINISTRATION
Practice aseptic techniques in withdrawing each dose to decrease the possibility of post-injection bacterial infections. Adequately clean and disinfect the stopper prior to entry with a sterile needle and syringe. Use only sterile needles, and use each needle only once.
The vial stopper may be punctured a maximum of 10 times.
The recommended dose ofMulti-Dose in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not with other drugs or solvents.
CONTRAINDICATIONS:
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.
ADEQUAN I.M. MULTI-DOSE
WARNINGS:
Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.
You must be logged in to post a review.
Reviews
There are no reviews yet.